US WorldMeds
US WorldMeds is a U.S.-based pharmaceutical company dedicated to improving the lives of patients with rare and challenging diseases through innovative specialty therapies. In 2026, the company achieved a major milestone with the full approval of TECELRA® (afamitresgene autoleucel) and expanded its indication to include pediatric patients aged 12 and older with unresectable or metastatic synovial sarcoma. US WorldMeds continues to strengthen its commitment to the sarcoma community through the development of additional therapies for synovial sarcoma and myxoid/round cell liposarcoma (MRCLS).
Beyond advancing new treatment options, US WorldMeds has distinguished itself through its commitment to partnership with the sarcoma community. By actively incorporating patient and advocacy perspectives into its development and regulatory efforts, the company has demonstrated a collaborative, patient-centered approach that helps ensure the needs and experiences of those affected by sarcoma help shape the future of care.
At a time when sarcoma remains underfunded and underserved, US WorldMeds’ leadership, innovation, and dedication to the patient voice continue to bring hope to patients and families nationwide. The Sarcoma Foundation of America is proud to recognize US WorldMeds with the Vision of Hope Award.
